Drug Trial Radar · NCT05541939
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Sep 13, 2022
Primary completion
Feb 17, 2023
Study completion Feb 17, 2023
Sponsor
- Lead sponsor
- Vogenx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).
Conditions
- Postbariatric Hypoglycemia
Interventions
MizagliflozinDrug
Encapsulated or Liquid Formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glucose Nadir After Mizagliflozin DosingTime frame: 0-3 hours following liquid meal
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Stanford
Palo Alto, California
University of Colorado / Anschutz Medical Campus
Aurora, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.